<DOC>
	<DOCNO>NCT01487629</DOCNO>
	<brief_summary>The purpose study compare morphological visual acuity outcomes associate 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injection treatment diabetic macular edema .</brief_summary>
	<brief_title>Bevacizumab Versus Ranibizumab Treatment Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Centerinvolving Diabetic macular edema unresponsive LASER therapy perform least 3 moth prior inclusion ; Best correct visual acuity equal worse 20/40 good 20/800 ; Central subfield macular thickness great 300 Âµm Aphakia Highrisk proliferative diabetic retinopathy Previous treatment DME past three month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>